Gilead Sciences has made a $200-million milestone payment to Nimbus Therapeutics, a biotechnology company headquartered in Cambridge, Massachusetts, related to Gilead’s allosteric acetyl-CoA carboxylase (ACC) inhibitor program with drug candidate NDI-010976 (now GS-0976). NDI-010976 is an investigational therapy that is being developed for treating liver disease. Gilead previously acquired it from Nimbus.

Gilead made an upfront payment of $400 million for the acquisition of Nimbus Apollo in April 2016 and may pay another potential $800 million in development-related payments, of which this milestone is the first. Nimbus has now received half of the total potential deal value within six months of the acquisition being completed.

Source: Nimbus